Akut koronart syndrom (ACS)

Introduction to the current care

Significant gaps exist between clinical guidelines and actual clinical practice for lipid management across Europe.
- 54% achieved the risk-based goal set in 2016.¹
- Only 33% met the more stringent 2019 risk-based goal.¹
75% of the patients were prescribed a HI statin at discharge after an event BUT 31% of the patients did not reach their LDL target of 1.4mmol/L during followup.²

10% risk of new MI/CVA/CV death within 100 days post-ACS.³
Briefly reducing very early on LDL-C after ACS even when you stop additional therapy led to better outcomes sustained over 4 years.

Good incentive to strike early, strike strong, even when they’re not adherent.

LDL-C lowering is accompanied by other things such as inflammatory marker decrease, plaque stabilisation with a thicker fibrous cap and less arterial inflammation.³

Challenge: Determining responsibility for implementation and managing the time required.

The more vascular beds, coronary, peripheral and neurological are affected, the higher the risk.

People with prediabetes and diabetes have a higher risk compared to non diabetes.

Higher baseline CV risk correlated with greater absolute risk reduction from LLT.⁵

Adopt early and aggressive LLT as the standard for both ACS and high-risk non-ACS patients.
Shift from conservative to aggressive approaches, ensuring optimal guideline-directed medical therapy from the start.

Ray-k et al Eur J Prev Cardiol 2021;28(11):1279
Schiele et al. Eur Heart J Acute CV Care 2024;13:46-54
Fox EHJ Aug 2010;31(21):2755-64 – Jernberg et al EHJ 2015;36:163
Schwartz et al EHJ 2023;44:1408-17
Jukema, JACC 2019 (prespecified analysis of the ODYSSEY OUTCOMES randomized controlled trial)